Strides Pharma Science
Strides Pharma Science Limited, commonly referred to as Strides, is a prominent player in the global pharmaceutical industry, headquartered in Bengaluru, India. Founded in 1990, the company has established a strong presence in various operational regions, including North America, Europe, and Africa. Strides focuses on the development, manufacturing, and marketing of a diverse range of pharmaceutical products, particularly in the areas of generic medications, complex generics, and over-the-counter (OTC) products. With a commitment to quality and innovation, Strides has achieved significant milestones, including the establishment of state-of-the-art manufacturing facilities and a robust pipeline of products. The company is recognised for its unique offerings in the injectable and oral dosage forms, positioning itself as a trusted partner in the healthcare sector. Strides Pharma Science continues to strengthen its market position through strategic collaborations and a dedication to meeting the evolving needs of patients worldwide.
DitchCarbon Score
How does Strides Pharma Science's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Strides Pharma Science's score of 34 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Strides Pharma Science's reported carbon emissions
In 2024, Strides Pharma Science reported total carbon emissions of approximately 53,760,000 kg CO2e for Scope 1, 17,099,000 kg CO2e for Scope 2, and 47,827,000 kg CO2e for Scope 3. This data indicates a comprehensive approach to emissions tracking, covering all three scopes of greenhouse gas emissions. In 2023, the company recorded Scope 1 emissions of about 5,331,800 kg CO2e and Scope 2 emissions of approximately 19,893,050 kg CO2e. The previous year, 2022, saw Scope 1 emissions at around 6,168,000 kg CO2e and Scope 2 emissions at about 19,385,000 kg CO2e. This trend suggests a potential focus on reducing emissions over time. Strides Pharma Science has committed to a long-term decarbonisation strategy aimed at achieving net-zero emissions by 2050. This strategy encompasses both Scope 1 and Scope 2 emissions, reflecting the company's dedication to contributing to the global Net Zero agenda. The commitment was formalised in 2023, with ongoing efforts to develop a detailed roadmap for implementation. The company is currently classified as "Committed" to net-zero targets, although specific near-term reduction targets have not been disclosed. This commitment aligns with industry standards and reflects a proactive stance in addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 6,168,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 19,385,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Strides Pharma Science is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
